MDM2 and breast carcinoma: The strong inhibitory effect of combination therapy on cell cycle thus provide a preclinical rationale to use MDM2 inhibitors with ER degraders to enhance the therapeutic effects of endocrine sensitive and resistant ER-positive p53wt breast cancer.